Journal of Cancer Research and Clinical Oncology最新文献

{"title":"After stent placement in patient with left colon cancer with intestinal obstruction safety and efficacy analysis.","authors":"Xin Yan, Teng Long, Yi Xiao, Linglong Peng, Haitao Gu, Yaxu Wang, Dengliang Liu","doi":"10.1007/s00432-025-06151-8","DOIUrl":"https://doi.org/10.1007/s00432-025-06151-8","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the safety and efficacy of intestinal stent placement as a bridge to surgery in patients with left colon cancer complicated by intestinal obstruction (LCCO).</p><p><strong>Methods: </strong>A retrospective cohort analysis was conducted on 111 patients diagnosed with LCCO at The Second Affiliated Hospital of Chongqing Medical University between January 2015 and August 2019. Patients were divided into two groups: the stent group (SG, n = 41) and the emergency surgery group (EG, n = 70). Primary endpoints included 3-year progression-free survival (PFS), local recurrence, and distant metastasis rates. Secondary endpoints encompassed 3-year overall survival (OS), intraoperative parameters (lymph node dissection, blood loss, operative time), enterostomy rate, postoperative complications, and hospital stay duration.</p><p><strong>Results: </strong>No significant differences were observed between SG and EG in 3-year PFS (59% vs. 41%, P = 0.091), OS (61% vs. 44%, P = 0.051), or metastasis rates (19.5% vs. 20%, P = 0.95). However, SG demonstrated superior short-term outcomes, including reduced intraoperative blood loss (60 mL vs. 78 mL, P = 0.02), shorter hospital stay (10.2 vs. 16.1 days, P < 0.001), lower enterostomy rate (0% vs. 100%, P < 0.001), and fewer postoperative complications (14.6% vs. 24.3%, P = 0.012).</p><p><strong>Conclusion: </strong>Stenting in patients with left colon cancer with obstruction can relieve the symptoms of intestinal obstruction in time. Compared with emergency open surgery, it has better short-term results and does not affect the long-term curative effect of the tumor.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"137"},"PeriodicalIF":2.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-intensity pulsed ultrasound affects proliferation and migration of human hepatocellular carcinoma cells.","authors":"Mingzhen Yang, Zhihui Lu, Bangzhong Liu, Guanghua Liu, Mingfang Shi, Ping Wang","doi":"10.1007/s00432-025-06183-0","DOIUrl":"https://doi.org/10.1007/s00432-025-06183-0","url":null,"abstract":"<p><strong>Purpose: </strong>Low-intensity pulsed ultrasound (LIPUS) is an effective ancillary treatment modality for various malignancies. However, the mechanisms underlying the role of LIPUS in cancer treatment have not been fully elucidated. We investigated the effects and underlying mechanism of LIPUS on the proliferation, apoptosis, migration, and invasion of hepatocellular carcinoma (HCC) cells.</p><p><strong>Methods: </strong>The HCC cell lines SMMC7721 and HCCLM3 were exposed to 1 MHz LIPUS at intensities of 0.5, 1.0, 1.5 W/cm² for 60 s. Cell morphology, viability, apoptosis, colony formation, migration, and invasion were assessed. Intracellular reactive oxygen species (ROS) levels and mitochondrial membrane potential were evaluated using a ROS assay kit and a JC-1 staining kit. Western blotting was performed to quantify changes in matrix metallopeptidases and epithelial-mesenchymal transition-related proteins. Orthotopic Hep3B-Luc tumor-bearing mice were treated with LIPUS at 1.5 W/cm² or 0 W/cm² and growth trend was measured.</p><p><strong>Results: </strong>The results showed that different intensities of ultrasound affected cellular activity, inhibited cell proliferation and cloning, facilitated intracellular cytoskeletal protein reorganization, and induced cell apoptosis, particularly at the intensity of 1.5 W/cm², through the ROS/mitochondria pathway. LIPUS enhanced SMCC7721 and HCCLM3 cell migration and invasion in a dose-dependent manner by regulating matrix metallopeptidases and epithelial-mesenchymal transition-related proteins. In vivo experiments confirmed the inhibitory effect of LIPUS at 1.5 W/cm² on tumor growth.</p><p><strong>Conclusions: </strong>Although LIPUS induced cell apoptosis and inhibited cell proliferation, it also promoted the invasion and metastasis of HCC cells under certain conditions, which was related to the regulation of matrix metallopeptidases and epithelial-mesenchymal transition-related proteins.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"136"},"PeriodicalIF":2.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revealing tumor microenvironment communication through m6A single-cell analysis and elucidating immunotherapeutic potentials for cutaneous melanoma (CM).","authors":"Lun Liu, Maxwell Andriano Kishengere, Xueming Xu, Zhanghui Yue","doi":"10.1007/s00432-025-06176-z","DOIUrl":"https://doi.org/10.1007/s00432-025-06176-z","url":null,"abstract":"<p><strong>Background: </strong>The methylation of N6-methyladenosine (m6A) RNA plays a crucial role in the genetic regulation of various cancers. While m6A modifications have been extensively studied in the tumor microenvironment (TME) of several malignancies, their role in cutaneous melanoma (CM) remains unexplored.</p><p><strong>Methods: </strong>Using Non-negative matrix factorization (NMF) analysis on single-cell RNA-seq data (GSE215121) from three CM samples obtained from public databases, 26 m6A RNA methylation regulators were utilized to determine TME subclusters, their expression, and function.</p><p><strong>Results: </strong>Six distinct TME cell types were identified and NMF clustering further revealed unique m6A-based subpopulations of cancer-associated fibroblasts and T cells. The prognostic model demonstrated strong predictive capabilities, particularly for fibroblast and T cell m6A clusters, and highlighted COL3A1 as a critical regulator of melanoma-fibroblast interactions.</p><p><strong>Conclusion: </strong>Highlighting the COL3A1 gene as a critical link and potential therapeutic target in melanoma could offer new avenues for targeted therapies and improve prognostic assessments in cutaneous melanoma.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"135"},"PeriodicalIF":2.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the role of HMGA2 plasma level as a diagnostic marker in bladder urothelial carcinoma patients.","authors":"Farah Khazem, Almoutassem Billah Zetoune","doi":"10.1007/s00432-025-06192-z","DOIUrl":"https://doi.org/10.1007/s00432-025-06192-z","url":null,"abstract":"<p><strong>Background: </strong>Bladder Cancer (BC) is an environmental cancer caused by exposure to a globally widespread carcinogen, which is smoking, and it is characterized by high rates of recurrence and mortality. High Mobility Group A2 (HMGA2) protein is an oncofetal protein that belongs to the HMG family proteins. It is involved in various stages of carcinogenesis and cancer progression. This study investigated the presence and levels of the HMGA2 protein in bladder urothelial carcinoma patients' plasma and in healthy individuals and their association with the clinicopathological features of bladder urothelial carcinoma.</p><p><strong>Methods: </strong>This case-control study included 80 individuals divided into two groups: a healthy group (n = 22) and a patient group with bladder urothelial carcinoma (n = 58). There were 16 patients with Muscle-Invasive Bladder Cancer (MIBC) and 42 patients with Non-Invasive Bladder Cancer (NMIBC) in the patients' cohort according to the European Association of Urology (EAU) classification. HMGA2 plasma levels were measured by Sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA). The statistical analysis was performed using IBM SPSS statistics (version 25) software. The t-test and the Mann-Whitney test were used.</p><p><strong>Results: </strong>Plasma HMGA2 protein levels were higher in the BC group than in the healthy group (P < 0.001), they also were higher in MIBC (pT2-pT3) than in NMIBC (pTa-pT1) (P < 0.001). HMGA2 plasma levels were higher in high grade BC patients than in low grade BC patients (P = 0.049).</p><p><strong>Conclusions: </strong>This study confirmed that the plasma HMGA2 protein level was higher in bladder cancer patients than in healthy individuals and that its elevated plasma levels were correlated with advanced stage and grade of BC; thus, the plasma HMGA2 protein level represents a potential non-invasive marker that could be included in bladder cancer diagnosis approach.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"134"},"PeriodicalIF":2.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MEK inhibitors for the treatment of immunotherapy-resistant, AGK-BRAF fusion advanced acral melanoma: a case report and literature review.","authors":"Yanling Zhang, Xifeng Zhang, Weikang Shao, Ji Gao, Mei Xiang, Yan Wang, Mengmeng Liu, Weizhen Zhang, Xianbin Liang","doi":"10.1007/s00432-025-06083-3","DOIUrl":"10.1007/s00432-025-06083-3","url":null,"abstract":"<p><strong>Purpose: </strong>Acral melanoma (AM), a rare and aggressive melanoma subtype with poor prognosis, presents unique challenges in treatment due to its distinct molecular and immune characteristics. This case report describes a patient with AM harboring an AGK-BRAF fusion mutation, aiming to explore potential mechanisms of resistance to current treatment modalities.</p><p><strong>Methods: </strong>We analyzed tumor tissue samples from the primary and metastatic lesions of the patient using next-generation sequencing (NGS) for genomic profiling and multiplex immunohistochemistry (mIHC) to assess the immune microenvironment. The patient underwent multiple lines of treatment, including immunotherapy, chemotherapy, and targeted therapy, with their clinical outcomes documented and evaluated.</p><p><strong>Results: </strong>The AGK-BRAF fusion mutation and its reciprocal BRAF-AGK rearrangement were identified in both primary and metastatic tumors. Immune profiling revealed abundant CD8 + T cells, PD-L1 + cells, and CD68 + macrophages localized predominantly in the tumor interstitial region, potentially explaining the poor response to immunotherapy. Despite initial disease stabilization with trametinib and lenvatinib, rapid progression occurred, highlighting tumor heterogeneity and limited efficacy of combined therapies.</p><p><strong>Conclusion: </strong>This case underscores the need for personalized approaches in treating AM, especially those with rare molecular alterations like AGK-BRAF fusion. Insights from genomic and immune profiling may inform future therapeutic strategies to overcome resistance and improve outcomes in this challenging melanoma subtype.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"133"},"PeriodicalIF":2.7,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear magnetic resonance-based lipid metabolite profiles for differentiation of patients with liver cirrhosis with and without hepatocellular carcinoma.","authors":"Luigi Nardone, Marianna Alunni-Fabbroni, Regina Schinner, Sabine Weber, Julia Mayerle, Eric Schiffer, Sebastian de Jel, Max Seidensticker, Peter Malfertheiner, Jens Ricke","doi":"10.1007/s00432-025-06178-x","DOIUrl":"10.1007/s00432-025-06178-x","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma is frequently unrecognized in its early stage limiting the access to the first therapeutic steps resulting in a low cure rate. Therefore, an early diagnosis is crucial. In this scenario the analysis of lipidome and metabolome emerged as a promising tool for early detection.</p><p><strong>Aims: </strong>Aim of the study was to characterize metabolomic profiles as novel markers of early hepatocellular carcinoma.</p><p><strong>Methods: </strong>Serum basal levels of metabolites, isolated from a cohort of 90 patients (n = 30 early stage; n = 30 advanced stage; n = 30 liver cirrhosis) were analysed using a nuclear magnetic resonance spectroscopy platform. To assess the predictive value of nuclear magnetic resonance profiles, we included the magnetic resonance imaging follow up of control patients with liver cirrhosis.</p><p><strong>Results: </strong>Significant differences were observed in the levels of individual parameters that included total cholesterol, LDL and HDL subclasses, Isoleucine, Valine, Triglycerides, Lactate, Alanine, Albumin, alpha Fetoprotein, Dimethylamine, Glycerol, and total Bilirubin levels in cancer compared to liver cirrhosis (p < 0.05). Furthermore, a significant difference in glycerol levels (p < 0.05) and a decreasing trend in dimethylamine were observed in cirrhotic patients who later developed HCC (16%, n = 5). Retrospective MRI analysis revealed precursor lesions in 3/5 patients, initially not classified as HCC due to their size and hemodynamic features.</p><p><strong>Conclusion: </strong>Nuclear magnetic resonance based assessment of lipidomic and metabolomic profiles permit the differentiation of cancer from liver cirrhosis. The data obtained suggests a possible role of lipidomic based serum profiles for early detection.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"131"},"PeriodicalIF":2.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of busulfan administration route including therapeutic drug monitoring in the conditioning regimen of pediatric patients prior to hematopoietic stem cell transplantation.","authors":"Stephanie Hämmerle, Jana Ernst, Regula Steiner, Tayfun Güngör, Till Milde, Bernd Gruhn","doi":"10.1007/s00432-025-06179-w","DOIUrl":"10.1007/s00432-025-06179-w","url":null,"abstract":"<p><strong>Purpose: </strong>Busulfan is an important myeloablative agent in various conditioning regimens prior to hematopoietic stem cell transplantation (HSCT) in pediatric patients. This retrospective study compares three different routes of busulfan administration and their impact on transplantation-related mortality (TRM) and overall survival (OS).</p><p><strong>Methods: </strong>The study included 250 pediatric patients with malignant and non-malignant diseases who underwent HSCT at the Department of Pediatrics, Jena University Hospital, Jena, Germany. One hundred forty-eight patients received busulfan orally without therapeutic drug monitoring (TDM) (group 1), 62 patients received busulfan intravenously (i.v.) without TDM (group 2) and 40 patients received busulfan i.v. with additional TDM (group 3).</p><p><strong>Results: </strong>The TRM rate at 5 years after transplantation for all patients was 40.5% for group 1, 25.2% for group 2, and 8.4% for group 3 (p < 0.001). The TRM rate at 5 years after transplantation for patients with malignant diseases only was 40.3% for group 1 compared to 28.4% for group 2 and 15.3% for group 3 (p = 0.051). For patients with non-malignant diseases, group 1 showed a TRM rate of 43.8% compared to 15.4% in group 2 and 4.6% in group 3 (p = 0.009). In addition, the 5-year OS rate for all patients was 39.9% for group 1, 61.2% for group 2, and 83.9% for group 3 (p < 0.001). Regarding the OS of the groups for patients with only malignant or only non-malignant diseases, we obtained similar results with p-values of p = 0.017 and p = 0.007, respectively. The cumulative incidence of hepatic sinusoidal obstruction syndrome (SOS) for patients with malignant diseases and a cumulative AUC > 85.0 mg/L x h was 55.6%, while patients with malignant diseases and a cumulative AUC < 85.0 mg/L x h showed a cumulative incidence of 11.1% (p = 0.038).</p><p><strong>Conclusion: </strong>In this study, we demonstrate that patients with i.v. administration of busulfan with TDM had a significantly lower rate of TRM and a significantly improved OS compared to patients who received i.v. administration of busulfan without TDM, who, in turn, had a better outcome than patients with oral busulfan administration. Additionally, these data emphasize the clinical relevance of AUC measurements in patients with malignant diseases to prevent hepatic SOS.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"132"},"PeriodicalIF":2.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving quality of care for cancer patients through oncological second opinions in a Comprehensive Cancer Center: adherence to second-opinion therapy recommendations.","authors":"Carla Schulmeyer, Peter A Fasching, Matthias W Beckmann, Lothar Häberle, Henriette Golcher, Peter J Goebell, Patrik Pöschke, Julius Emons","doi":"10.1007/s00432-025-06149-2","DOIUrl":"10.1007/s00432-025-06149-2","url":null,"abstract":"<p><strong>Purpose: </strong>Receiving treatment in certified oncological centers and obtaining a second medical opinion has been proven to enhance both the quality and cost-effectiveness of care for oncological patients. Interdisciplinary care optimizes the treatment of oncological patients by validating the diagnosis and treatment recommendation, emphasizes translational research, and applies oncological therapies in a more target-oriented manner. This study aims to examine the extent of patient adherence to second medical opinions provided at the Comprehensive Cancer Center Erlangen-Metropolitan Area Nuremberg (CCC Erlangen-EMN) and investigates how specific patient characteristics such as age, gender, and type of cancer diagnosis influence the likelihood of adhering to a second opinion.</p><p><strong>Methods: </strong>This is a prospective, single-center observational study supported by the local statutory health-insurance body (Allgemeine Ortskrankenkasse, AOK). A total of 584 male and female patients with cancer in the fields of urology, gynecology, gastroenterology, or sarcoma, seeking a second medical opinion were assessed for their adherence to the second opinion. Levels of adherence in patient subgroups were compared using appropriate statistical tests. Correction for multiple testing was not performed, due to the exploratory nature of the study.</p><p><strong>Results: </strong>Almost 75% of the patients adhered to the second opinion recommendations and an additional 10% partially followed them. Men adhered to the second opinion recommendation slightly more often (79.1%) than women (70.7%; chi-square test, P = 0.01). At 83%, second-opinion adherence was highest among patients who had received an incomplete but guideline-compliant first opinion. If the first opinion was not guideline-compliant, about 67% adhered to the second opinion. Adherence to second opinions was not significantly influenced by whether the initial therapy recommendation adhered to guidelines (Fisher's test, P = 0.16 for all departments, P = 0.27 for the gynecology department). Most patients adhered to the second opinion after primary therapy (92.9%).</p><p><strong>Conclusions: </strong>More than two-thirds of patients ultimately followed the recommendation provided in the second opinion. The results of this study enhance our understanding of patient adherence to medical advice and treatment regimens. This study demonstrated that the majority of patients adhere to second opinions and highlighted the feasibility of easy access to second opinions from a certified cancer center. Women adhered slightly less to second opinions than men. More detailed and comprehensive therapy recommendations could potentially enhance adherence rates in the future.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"130"},"PeriodicalIF":2.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of radiotherapy combined with targeted therapy and immunotherapy for lymph node metastasis of liver cancer.","authors":"Huamei Yan, Jianliang Xu, Zhenghuan Li, Nuoya Li, Xianyu Guo, Manya Wu, Donghui Wang, Nan Lin, Jie Dong, Xiangying Xu","doi":"10.1007/s00432-025-06182-1","DOIUrl":"10.1007/s00432-025-06182-1","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the efficacy and safety of radiotherapy combined with targeted therapy and immunotherapy for liver cancer with lymph node metastasis (LNM).</p><p><strong>Methods: </strong>We analysed patients who received radiotherapy for liver cancer with LNM in our hospital from June 2020 to June 2023. 62 patients were enrolled in this study, who received radiotherapy with a median radiation dose of 60.0 Gy, combined with targeted therapy and/or immunotherapy. The objective response rate (ORR), overall survival (OS), progression free survival (PFS), and adverse events were observed to evaluate treatment efficacy and safety.</p><p><strong>Results: </strong>With a median follow-up of 18.5 months, the best ORR was 90.3%. The median OS was 26.0 months. The 1-year and 2-year OS rates were 78.93% and 57.37%, respectively. The median PFS was 17.0 months, and the 1-year and 2-year PFS rates were 59.06% and 49.22%, respectively. Multivariate analysis showed that alanine aminotransferase (HR = 2.34, 95% CI 1.07-5.11, P = 0.033), prothrombin time (HR = 4.51, 95% CI 1.76-11.57, P = 0.002), alpha fetal protein (HR = 2.94, 95% CI 1.34-6.45, P = 0.007), and the volume of LNM (HR = 3.05, 95% CI 1.25-7.46, P = 0.014) were independent predictors for OS, while non-regional LNM (HR = 3.19, 95% CI 1.24-8.16, P = 0.016) was an independent predictor for PFS. Toxicity was generally mild and moderate.</p><p><strong>Conclusions: </strong>Radiotherapy combined with targeted therapy and immunotherapy is an effective treatment option, and expected to become new treatment strategy for liver cancer with LNM.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"129"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: a case of R0 resection in a patient with PD-L1-negative, microsatellite-stabilized advanced pancreatic cancer after down-stage treatment with a PD-1 inhibitor in combination with chemotherapy.","authors":"Junqiang Dang, Qingqiang Wang, Yanling Yang, Lin Shang, Zeping Kang, Yu Jiang, Yanshun Ren, Hongjun Xiang","doi":"10.1007/s00432-025-06147-4","DOIUrl":"10.1007/s00432-025-06147-4","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal tumor with high morbidity and mortality. Despite advances in diagnostic and therapeutic modalities, the outcome and prognosis of PDAC remain poor. Most patients have locally advanced disease (30%-35%) or distant metastases (50%-55%) at the time of diagnosis. The treatment of unresectable pancreatic ductal adenocarcinoma (UR-PDAC) remains an urgent problem. In this study, we report that a patient with UR-PDAC underwent significant tumor shrinkage after PD-1 inhibitor combination chemotherapy, and obtained R0 (pathologically negative margin) resection and long-term survival.</p><p><strong>Case presentation: </strong>A 51-year-old woman was diagnosed with pancreatic cancer (stage III). She underwent 3 cycles of preoperative neoadjuvant therapy (NAT) with programmed cell death protein 1 (PD-1) antibody in combination with chemotherapy and the tumor shrank from 4.0 × 3.3 cm to 0.9 cm without significant adverse effects. The patient underwent conversion surgery (CS) and achieved R0 resection, and no tumor cells remained as confirmed by pathology.</p><p><strong>Conclusion: </strong>PD-1 antibody combination chemotherapy regimens have significant efficacy and do not add additional side effects in UR-PDAC patients, heralding advances in UR-PDAC treatment. We may have a way to give UR-PDAC patients access to curative treatment and long-term survival. This case of UR-PDAC patient with PD-L1-negative and microsatellite stability (MSS) gives us a more comprehensive understanding of the treatment options of immune-combination chemotherapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"128"},"PeriodicalIF":2.7,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}